Can-Fite Biopharma - ADR opened higher at $1.60, compared with its previous close of $1.55. In the last trading session, the stock traded between $1.46 and $1.60. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Can-Fite Biopharma - ADR is now worth
$ 0.53
Resulting in a loss of
$ 99.47 (99.47%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.07 (-4.52%)
Day High
$1.60
Day Low
$1.46
Day Open
$1.60
Prev Close
$1.55
Volume
88,617
1W Return
-11.27%
1M Return
-24.87%
3M Return
-55.72%
6M Return
-55.95%
1Y Return
-81.29%
Market Cap ($ Mn)
5
PE Ratio
-
PB Ratio
0.80
PEG Ratio
-
ROE
-193.82%
ROCE
-155.96%
EPS (TTM)
$-4.05
1 Week
-11.27%
1 Month
-24.87%
3 Months
-55.72%
6 Months
-55.95%
9 Months
-66.36%
Can-Fite reports 10-year cancer-free survival in liver cancer trial
Patient with advanced liver cancer reached 10 years of overall survival. Individual remains cancer-free and in good health after treatment with Namodenoson. Outcome follows previous report of nine-year survival in November 2025. Data comes from Can-Fite BioPharma's completed Phase II study.
3 days agoCan-Fite BioPharma files prospectus for 6.599 million share offering
Can-Fite BioPharma filed a prospectus with the SEC. Offering involves approximately 6.599 million ordinary shares. Sale is on behalf of selling shareholders, not the company.
1mo agoCan-Fite H1FY26 Results: Net loss narrows 5.5% to $4.6 million
Net loss narrowed 5.5% YoY to $4.60 million for H1 2026. Revenue remained flat at $0.20 million from out-licensing advances. R&D expenses rose 13.9% to $3.45 million due to trial acceleration. Blinded survival data in Phase III liver cancer study exceeds expectations. Cash position decreased to $7.03 million amid operating losses.
2mo agoCan-Fite BioPharma secures $4M via warrant exercise amid trial update
Can-Fite BioPharma secured $4 million gross proceeds via warrant exercise. Company reduced exercise price from $5 to $2.50 per ADS to facilitate deal. Pivotal Phase 3 liver cancer trial shows extended blinded overall survival. Management assessing earlier interim analysis timeline for Namodenoson study.
2mo agoCan-Fite BioPharma raises $4M via warrant exercise at $2.50 per ADS
Can-Fite BioPharma exercises warrants for 1,591,738 ADSs at $2.50 each. Gross proceeds expected to be approximately $4.0 million. New unregistered warrants issued for up to 3,183,476 ADSs. Closing expected on or about September 3, 2026.
2mo agoCan-Fite sees longer-than-expected survival in pivotal HCC trial
Blinded overall survival in Can-Fite's Phase III Namodenoson study for advanced HCC exceeds initial design assumptions. Data reflects pooled population of patients receiving both drug and placebo, so no efficacy conclusions can yet be drawn. Company is evaluating an earlier timing for the planned interim analysis to assess treatment group differences. Study targets patients with advanced HCC and underlying Child-Pugh B7 cirrhosis with a 2:1 randomization ratio.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Can-Fite Biopharma - ADR is now worth
$ 0.53
Resulting in a loss of
$ 99.47 (99.47%)
Note: Past profits do not guarantee future returns.
